Rorc restrains the potency of ST2+ regulatory T cells in ameliorating intestinal graft-versus-host disease by Yang, Jinfeng et al.
1insight.jci.org   https://doi.org/10.1172/jci.insight.122014
R E S E A R C H  A R T I C L E
Authorship note: JY, AR, DKR, and 
ML contributed equally to this work. 
BRB and SP contributed equally to 
this work.
Conflict of interest: SP has a patent 
(US20130115232A1), “Methods of 
detection of graft-versus-host disease,” 
licensed to Viracor-IBT Laboratories.
License: Copyright 2019, American 
Society for Clinical Investigation.
Submitted: May 3, 2018 
Accepted: January 25, 2019 
Published: March 7, 2019
Reference information: 
JCI Insight. 2019;4(5):e122014. 
https://doi.org/10.1172/jci.
insight.122014.
Rorc restrains the potency of ST2+ 
regulatory T cells in ameliorating 
intestinal graft-versus-host disease
Jinfeng Yang,1 Abdulraouf Ramadan,1 Dawn K. Reichenbach,2 Michael Loschi,2 Jilu Zhang,1  
Brad Griesenauer,1 Hong Liu,1 Keli L. Hippen,2 Bruce R Blazar,2 and Sophie Paczesny1
1Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA. 2Department of Pediatrics, 
University of Minnesota, Minneapolis, Minnesota, USA.
Introduction
Allogeneic hematopoietic cell transplantation (allo-HCT) is an essential therapeutic modality for patients 
with hematological malignancies and benign blood disorders (1). Unfortunately, graft-versus-host disease 
(GVHD) remains the major complication of  allo-HCT and is associated with high mortality, morbidity, 
and health care costs (2, 3). Several studies have demonstrated that CD4+Foxp3+ Tregs inhibit prolifera-
tion of  conventional T cells (Tcons), limiting acute GVHD (aGVHD) lethality while preserving graph-ver-
sus-leukemia (GVL) activity (4–7). Clinical adoptive transfer experiments showed the safety and efficacy 
of  Treg infusions (8–10), suggesting that Treg-based cellular therapy is a promising approach for aGVHD 
prevention. Despite research into the role of  Tregs in aGVHD, the precise mechanisms through which 
Tregs control alloreactive immune responses have not been fully elucidated. Tregs are heterogeneous pop-
ulations that show a high degree of  phenotypic and functional diversity (11). Two studies have shown 
that transplantation of  CD62Lhi Tregs into irradiated MHC-mismatched recipients protected them from 
lethal aGVHD because the Tregs interfered with the activation and expansion of  effector T cells (Teffs) in 
secondary lymphoid organs early after HCT (12, 13). However, the functional nonlymphoid tissue Treg 
subsets that have the greatest impact on intestinal aGVHD remain largely unknown. Based on the location 
of  induction, Tregs can be divided into two different subsets: naturally occurring thymus-derived Tregs 
(tTregs) and those conditionally expanded in the periphery from Tcons (pTregs) (10, 14). Additionally, 
Tregs can be separated into functional subsets according to their surface phenotype. These include a central 
Treg population, which has circulatory features similar to those of  naive Tcons (CCR7+CD62L+), and sev-
eral activated Treg populations that are similar to effector Tcons (CCR7loCD62LloCD44hiKLRG1+CD103+) 
(15). Tregs can also be described based upon effector cytokine expression and transcriptomics (16, 17). 
Soluble stimulation–2 (ST2) is increased during graft-versus-host disease (GVHD), while Tregs 
that express ST2 prevent GVHD through unknown mechanisms. Transplantation of Foxp3– T cells 
and Tregs that were collected and sorted from different Foxp3 reporter mice indicated that in 
mice that developed GVHD, ST2+ Tregs were thymus derived and predominantly localized to the 
intestine. ST2–/– Treg transplantation was associated with reduced total intestinal Treg frequency 
and activation. ST2–/– versus WT intestinal Treg transcriptomes showed decreased Treg functional 
markers and, reciprocally, increased Rorc expression. Rorc–/– T cells transplantation enhanced 
the frequency and function of intestinal ST2+ Tregs and reduced GVHD through decreased gut-
infiltrating soluble ST2–producing type 1 and increased IL-4/IL-10–producing type 2 T cells. 
Cotransfer of ST2+ Tregs sorted from Rorc–/– mice with WT CD25-depleted T cells decreased GVHD 
severity and mortality, increased intestinal ST2+KLRG1+ Tregs, and decreased type 1 T cells after 
transplantation, indicating an intrinsic mechanism. Ex vivo IL-33–stimulated Tregs (TregIL-33) 
expressed higher amphiregulin and displayed better immunosuppression, and adoptive transfer 
prevented GVHD better than control Tregs or TregIL-33 cultured with IL-23/IL-17. Amphiregulin 
blockade by neutralizing antibody in vivo abolished the protective effect of TregIL-33. Our data show 
that inverse expression of ST2 and RORγt in intestinal Tregs determines GVHD and that TregIL-33 has 
potential as a cellular therapy avenue for preventing GVHD.
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Activated Tregs are CD62Llo, display signs of  recent TCR stimulation, and reside in nonlymphoid tissues 
including skin, liver, and gut (18), which are also major aGVHD target organs.
Recent studies have described high stimulation-2 (ST2) expression on specialized Tregs and show 
that they are enriched in nonlymphoid tissues (19–22). ST2, also called IL-33 receptor, has 2 main splice 
isoforms from a single transcript dependent on the promoter being used: the distal promoter region when 
bound to GATA transcription factors transcribes the membrane receptor of  ST2; and when PMA-re-
sponsive elements bind to the proximal promoter, soluble ST2 (sST2) is transcribed and acts as a decoy 
receptor for IL-33 (23). In the colon, IL-33 signaling through ST2 in Tregs contributes to the mainte-
nance of  Foxp3 expression under inflammatory conditions, allowing Tregs to exert their suppressive 
function in the inflammatory niche by inhibiting the intestinal Teff  response (19). ST2 is also required 
for the development of  visceral adipose tissue–resident Tregs, which limits obesity-associated inflam-
mation (21). Recently, a genome-wide DNA methylation landscape showed that ST2+ Tregs localize in 
specialized tissues, specifically in the skin, gonadal visceral adipose tissue, and liver (22). We previously 
showed that elevated plasma sST2 in mice and humans is a risk factor of  therapy-resistant aGVHD 
and death (20, 24). Intestinal stromal, endothelial, and type 1 T cells were the major cellular source of  
sST2 during aGVHD (20). This enhanced sST2 presence has been shown to inhibit the production of  
the type 2 cytokines IL-4 and IL-5 but not the type 1 cytokine IFN-γ (25). We have also shown that ST2 
blockade with a neutralizing antibody reduces plasma sST2 as well as frequencies of  sST2-producing T 
cells while maintaining membrane ST2-expressing T cells (Th2 and ST2+ Tregs) during aGVHD (20). 
IL-33 signaling through ST2 helps induce Th2-associated cytokines (26) and IL-9–producing T cells (27), 
and peri-transplant IL-33 administration allows expansion of  Tregs in aGVHD models (28). These find-
ings suggest a nonredundant role of  ST2 in functional specialization and Treg homeostasis. Herein, we 
studied nonlymphoid tissue ST2+ Tregs. We uncovered mechanisms underlying the inverse relationship 
between ST2 and RORγt expression in intestinal Tregs during aGVHD, and our work suggests novel 
therapeutic targets within Tregs during aGVHD and the potential to ultimately establish a practical Treg-
based cellular therapy for aGVHD prevention.
Results
ST2+ Tregs are expanded from thymic Tregs and localized in the target organs after HCT. Given their natural pres-
ence, high stability, and crucial function in maintaining homeostasis, we hypothesized that ST2+ Tregs in 
nonlymphoid tissues are predominantly thymus derived. To determine whether ST2+ Tregs were either 
thymic (tTregs) or peripheral (pTregs), donor grafts comprising CD25-depleted T cells and Tregs were 
sorted from 2 different C57BL/6 (B6) Foxp3 reporter mouse strains to trace the thymic or peripheral origin 
of  donor Tregs, as previously described (29). Mice received WT B6 Foxp3RFP CD25-depleted total T cells, 
and WT or ST2–/– B6 Foxp3GFP sorted Tregs with WT B6 T cell–depleted (TCD) BM cells in a minor-mis-
matched (B6, H-2b→C3H.SW, H-2b; miH) HCT model. Ex vivo analysis of  the gut on day 10 after allo-
HCT showed a low frequency of  Foxp3RFP in both WT and ST2–/– groups, suggesting minimum de novo 
generation of  pTregs during aGVHD, as has been shown previously (30) (Supplemental Figure 1A; sup-
plemental material available online with this article; https://doi.org/10.1172/jci.insight.122014DS1). In 
contrast, we found a higher frequency of  tTregs in the gut in mice receiving WT Foxp3GFP Tregs compared 
with those that received ST2–/– Foxp3GFP Tregs. Therefore, most Tregs found in the gut were derived from 
donor tTregs and not from conversion of  Tcons to pTregs. Moreover, loss of  ST2 on donor tTregs reduced 
tTreg frequency after allo-HCT in the inflamed aGVHD target organs (gut, liver) but not in secondary 
lymphoid organs (Supplemental Figure 1A), confirming that ST2+ Tregs are tissue-resident Tregs (21, 22).
ST2 deficiency on tTregs alters their activation and function after HCT. The finding that mice transplanted 
with ST2–/– Tregs had a lower frequency of  total Foxp3+ Tregs (20) suggested that the ST2/IL-33 axis may 
contribute to activation and function of  donor tTregs. In the miH GVHD model with Treg co-adoptive 
transfer, we found that ST2–/– Foxp3GFP tTregs showed lower expression of  the activation markers CD69 and 
KLRG1, in contrast to WT Foxp3GFP tTregs (Supplemental Figure 1B), and gut-localized ST2–/– Foxp3GFP 
tTregs produced less IL-10 and LAG3 (Supplemental Figure 1C). Of note, no difference in activation mark-
ers and IL-10 production was seen for pTregs (data not shown). This is the first analysis to our knowledge 
of  gut-localized donor WT versus ST2–/– Tregs that were adoptively transferred before the onset of  aGVHD 
intestinal pathology. The data show that intestinal ST2+ Tregs have high KLRG1, CD69, and LAG3 expres-
sion, and produce high levels of  IL-10.
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Transcriptome analysis of  intestinal ST2–/– versus WT Tregs in 2 aGVHD models reveals inverse expression of  
Il1rl1 and Rorc. We have previously shown that co-adoptive transfer of  ST2–/– Foxp3GFP Tregs and Tcons 
eradicates the protective impact of  WT Tregs in aGVHD (20). To further understand the mechanism, 
we performed transcriptome analysis of  sorted intestinal Foxp3GFP Tregs from aGVHD mice receiving 
WT CD25-depleted total T cells with either WT or ST2–/– Foxp3GFP Tregs in both major-mismatched (B6, 
H-2b→BALB/c, H-2d; Mhc) and miH aGVHD models. We found that ST2–/– versus WT Foxp3GFP Tregs 
showed decreased expression of  key molecules needed for Treg function such as Foxp3, Il2ra, Icos, Il27, 
Ctla4, and Ahr (Figure 1 and Supplemental Table 1). Loss of  Foxp3 on Tregs led to increased expression 
of  inflammatory molecules in intestinal ST2–/– versus WT Tregs in both models (Supplemental Table 2). 
Strikingly, among all the upregulated genes in intestinal ST2–/– Foxp3GFP Tregs, transcription of  RAR-re-
lated orphan receptor c (Rorc), which encodes RORγt, the essential gene for proinflammatory IL-17+ T cell 
development (20, 31–33), was the most upregulated transcript in ST2–/– versus WT Foxp3GFP Tregs isolated 
from the gut in both models (Figure 1). Therefore, we next explored the role of  the IL-17 transcription fac-
tor Rorc in intestinal Tregs analyzed under steady-state and inflamed gut conditions.
Rorc deficiency shows an increase in ST2+ Tregs in the steady-state gut. The transcriptome finding led us to 
investigate the frequency and function of  Tregs in the gut of  naive mice deficient for Rorc. Isolation and 
staining of  intestinal T cells showed a significant increase in Treg frequency in the gut of  Rorc–/– mice 
compared with WT mice (Figure 2A). Interestingly, ~55% of  Tregs from Rorc–/– mice were ST2+ com-
pared with only ~12% ST2+ Tregs from WT mice (Figure 2B). Our data suggest that at steady state, Rorc 
deficiency in intestinal T cells leads to increased frequency of  Foxp3+ Tregs among all T cells, particularly 
ST2+ Tregs. Rorc–/– versus WT mice showed increased total Treg frequencies in liver (2.74% ± 0.03% vs. 
11.4% ± 0.9%, no difference in ST2+ Tregs), and spleen (13.8% ± 0.2% vs. 23.8% ± 1.3%, no difference in 
ST2+ Tregs) but not in peripheral blood; lymph nodes were not tested. These data suggest a preferentially 
nonlymphoid-specific mechanism to support gut ST2+ Treg accumulation likely dependent on responses to 
local endogenous antigen stimulation following HCT, analogous to the local suppressive effects of  tTregs in 
draining lymph nodes of  mice with autoimmune ovarian disease (34).
Rorc deficiency alleviates aGVHD severity via increased frequencies of  functional ST2+ Tregs in the inflamed 
gut and restoring the Tcon/Treg balance. Mice receiving donor Rorc–/– T cells showed less-severe aGVHD 
and increased survival compared with those receiving WT T cells in the miH GVHD model (Figure 2C). 
Lower aGVHD scores were correlated with decreased systemic sST2 and IFN-γ levels in plasma of  mice 
receiving Rorc–/– T cells (Figure 2D). Infiltrated intestinal Tregs, particularly ST2+ Treg frequencies of  
recipients receiving Rorc–/– T cells, were significantly higher as compared with those receiving WT T 
cells (Figure 2, E and F). Ex vivo analysis of  these sorted infiltrated intestinal Tregs from mice receiv-
ing Rorc–/– T cells showed that they expressed significantly higher levels of  membrane-bound ST2 than 
those receiving WT T cells. As expected, sST2 was not detected in Tregs (Figure 2G). These ST2+ Tregs 
derived from Rorc–/– T cells also showed higher expression of  TIGIT and Helios (Figure 2H), suggest-
ing an increased suppressor function compared with WT Tregs even in the context of  inflammation, 
consistent with studies of  Treg-specific TIGIT (35) or Helios (36) deletion. We have previously shown 
that co-adoptive transfer of  ST2+ Tregs mediated less-severe aGVHD by restoring a Tcon/Treg balance 
specifically by reducing Tcons producing sST2 and increasing Tcons expressing membrane-bound ST2 
(20). Therefore, we next explored whether this counterbalance would also happen with donor Rorc–/– T 
cells in mice undergoing HCT. Indeed, we found that Tcons from Rorc–/– recipients produced less sST2 
as compared with WT Tcons while expressing higher levels of  membrane-bound ST2 than their WT 
counterparts (Figure 2, I and J). Recipients of  Rorc–/– donor T cells showed lower frequencies of  IFN-γ–
producing T cells in the gut on day 14 after HCT (Figure 2K). At the same time, and along with the 
increased frequency of  ST2+ Tregs, recipients of  Rorc–/– donor T cells showed increased percentages of  
Th2 cytokine IL-4 and of  IL-10 in Tcons (Figure 2L). These data indicate that T cells from Rorc–/– mice 
have a preferential role in exerting a protective effect against aGVHD.
Rorc–/– ST2+ Tregs decrease GVHD severity and mortality, increase intestinal ST2+ KLRG1+ Tregs, and decrease 
intestinal type 1 T cells after HCT through an intrinsic mechanism. To verify whether ST2+ Tregs from Rorc–/– 
mice were qualitatively different from WT ST2+ Tregs, we sorted ST2+ Tregs from Rorc–/– or WT mice and 
cotransplanted each at a 1:10 ratio with CD25-depleted WT T cells in an miH model. ST2+ Tregs from 
Rorc–/– mice cotransplanted at the same ratio as WT ST2+ Tregs were able to further decrease GVHD 
scores and mortality (Figure 3A). Consequently, on day 14 after HCT, in recipients receiving Rorc–/– ST2+ 
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Tregs, approximately 45% of  intestinal Tregs were ST2+ versus 30% in recipients receiving WT ST2+ Tregs 
(Figure 3B). These Rorc–/– ST2+ Tregs after HCT express more KLRG1 and Helios (Figure 3C). We also 
looked at the impact on effector intestinal CD4+ and CD8+ T cells at the same time after HCT. We showed 
decreased total lymphocyte infiltration (Figure 3D) and lower frequencies of  IFN-γ–producing CD4+ and 
CD8+ T cells in the gastrointestinal tract of  mice receiving Rorc–/– ST2+ Tregs versus WT ST2+ Tregs (Fig-
ure 3E). These data suggest an intrinsic role of  Rorc in ST2+ Tregs in aGVHD.
Ex vivo polyclonal Tregs cultured with supplemental IL-33 (TregIL-33) express more ST2, activation markers, 
amphiregulin, and immunosuppressive function compared with those cultured either without IL-33 or with IL-33 
and IL-23/IL-17. We next wondered whether we could use these ST2+ Tregs as a cellular therapy avenue 
for preventing GVHD. IL-33 signaling in Tregs has been shown to (i) elicit amphiregulin production that 
enhances repair ability for injured muscles (37), independent of  their suppressive activity on Teffs (38); 
and (ii) induce superior Teff  immunosuppression ex vivo (19, 39) and in a colitis model (19). Therefore, 
we hypothesized that IL-33/ST2 stimulation will drive superior ST2+ Treg function through these dual 
properties. To observe whether IL-33/ST2 upregulation of  amphiregulin expression would be advanta-
geous over current Treg culture methods, we used a short-term culture (3 days) of  Tregs to facilitate clin-
ical translation. Because IL-23, a key proinflammatory cytokine in the maintenance and amplification 
of  Th17/Tc17, can restrain Treg responses by inhibiting IL-33 responsiveness (19), we tested whether 
adding IL-23 + IL-17 would subvert the beneficial effect of  IL-33. Using ex vivo polyclonal Tregs from 
B6 donors cultured with IL-2 (control Tregs) versus IL-2 + IL-33 (TregIL-33) versus IL-2 + IL-33 + IL-2 
3+ IL-17, we found that adding IL-33 doubled the frequencies of  ST2+ Tregs compared with control 
Tregs, and adding IL-23 + IL-17 reversed this effect (Figure 4A). Markers of  Treg activation (KLRG1) 
and function (Helios, LAG3) were augmented in TregIL-33 compared with other Treg conditions (Figure 
4B). TregIL-33 also expressed more amphiregulin protein and RNA than Tregs cultured in either of  the 
2 other conditions (Figure 4C). To evaluate immunosuppressive function, Tregs were added to CD4+ 
and CD8+ Teffs at 1:1 to 1:12 ratios. The percentage of  CD4 suppression by TregIL-33 as compared with 
control Tregs was significant only at a physiological ratio of  1:12; CD8 suppression at a ratio of  1:3 was 
the most significant (Supplemental Figure 2A). For both CD4 and CD8 proliferation suppression, adding 
IL-23/IL-17 significantly inhibited the superior immunosuppressive effect of  IL-33 starting at ratio of  
1:3 for CD4+ Teffs and 1:1 for CD8+ Teffs. To verify whether the enhanced suppressive ability of  TregIL-33 
was directly due to the expression of  ST2, WT versus ST2–/– Tregs were cultured with/without IL-33 and 
cocultured with Teffs at Treg/Teff  ratios of  1:12 and 1:24 respectively. ST2–/– Tregs inhibited Teff  prolif-
eration to the same extent as WT Tregs in vitro. TregIL-33 showed enhanced suppressor function on CD4
+ 
T cells compared with Tregs cultured without IL-33 or ST2–/– Tregs. No difference was found between 
ST2–/– Tregs cultured with/without IL-33 (Supplemental Figure 2B). These data suggest that TregIL-33 
Figure 1. Transcriptome analysis of intestinal ST2–/– versus WT Tregs in 2 aGVHD models. Transcriptome analysis of 
Foxp3GFP Tregs sorted from the gut of a pool of 3–5 BALB/c or C3H.SW mice receiving WT CD25-depleted total T cells 
with either WT or ST2–/– Foxp3GFP Tregs (ratio 3:1 for BALB/c and 5:1 for C3H.SW) on day 14 and day 10 after HCT, respec-
tively. Data shown as ratio of fold change between sorted ST2–/– and WT Foxp3GFP Tregs log2 transformed.
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increase their immunosuppressive capacity on Teffs, while adding Th17-related cytokines to TregIL-33 
counteracted this effect, as previously shown (19, 39).
Adoptive transfer of  ex vivo cultured donor TregIL-33 leads to superior protection from aGVHD compared 
with those cultured either without IL-33 or with IL-33 and IL-23/IL-17, and amphiregulin blockade abolishes 
the protective effect of  TregIL-33. We next examined the in vivo capacity of  donor TregIL-33 to protect from 
aGVHD intestinal damage by co-adoptive transfer of  Tregs cultured in the 3 aforementioned condi-
tions in both Mhc and miH aGVHD models. We used a more stringent ratio of  1 donor Tregs per 20 
donor Tcons (5% of  total T cells). In both aGVHD models, mice receiving TregIL-33 at a 1:20 ratio with 
CD25-depleted total T cells showed significantly less-severe aGVHD and better survival compared 
with those receiving Tregs cultured with IL-2 alone or IL-2 + IL-33 + IL-23 + IL-17 (Figure 5A and 
Supplemental Figure 3A). Ex vivo analysis of  intestinal T cells showed that mice receiving TregIL-33 
exhibited decreased intestinal lymphocyte infiltration and increased Treg and ST2+ Treg frequencies 
on day 10 after HCT, whereas T-bet–, IFN-γ–, RORγt-, and IL-17–expressing Tcons were decreased 
Figure 2. Rorc deficiency alleviates aGVHD severity associated with increased frequencies of functional ST2+ Tregs in the inflamed intestine and 
restoration of Tcon/Treg balance. (A) Representative plots of Foxp3 expression on CD4+ T cells in gut of naive B6 WT or Rorc–/– mice. n = 3, data 
are shown as mean ± SEM; unpaired t test, ***P < 0.001. (B) Representative plots of ST2 expression on Tregs in gut of naive B6 WT or Rorc–/– mice, 
respectively. n = 3, data are shown as mean ± SEM; unpaired t test, *P < 0.05. (C) Clinical score and survival curve of lethally irradiated C3H.SW mice 
receiving B6 WT TCD BM with WT or Rorc–/– donor T cells. n = 5, data are shown as mean ± SEM; unpaired t test, **P < 0.01 for clinical score; a log-
rank test was used for survival analysis,**P < 0.01. (D) sST2 and IFN-γ concentrations in plasma collected from the mice described above at the indi-
cated time points after HCT. n = 3, data are shown as mean ± SEM; unpaired t test, *P < 0.05. (E) Representative plots of Foxp3 expression on CD4+ 
T cells isolated from the gut of C3H.SW mice receiving WT or Rorc–/– T cells on day 14 after allo-HCT, n = 3, data are shown as mean ± SEM; unpaired 
t test, *P < 0.05. (F) Representative plots of ST2 expression on Tregs isolated from the gut of C3H.SW mice receiving WT or Rorc–/– T cells on day 14 
after allo-HCT. n = 3, data are shown as mean ± SEM; unpaired t test, **P < 0.01. (G) mRNA expression of ST2 on Tregs sorted from the gut of mice 
in C on day 14 after allo-HCT. n = 3, data are shown as mean ± SEM; unpaired t test, **P < 0.01. (H) Representative plots of ST2, TIGIT, and Helios 
expression on Foxp3+ Tregs from the gut of C3H.SW mice receiving WT or Rorc–/– T cells on day 14 after HCT. n = 3, data are shown as mean ± SEM; 
unpaired t test, *P < 0.05, **P < 0.01. (I and J) mRNA expression of ST2 and sST2 by sorted Foxp3GFP– effector T cells isolated from the gut of mice in 
C on day 14 after HCT. n = 3, data are shown as mean ± SEM; unpaired t test, **P < 0.01, ***P < 0.001. (K and L) Representative plots of IFN-γ, IL-17, 
IL-4, and IL-10 production by Foxp3GFP– effector T cells from the gut of C3H.SW mice receiving WT or Rorc–/– T cells on day 14 after HCT. n = 3, data are 
shown as mean ± SEM; unpaired t test, *P < 0.05.
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and less proliferated (Figure 5B and Supplemental Figure 3B). To verify that the effects of  IL-33 on 
Tregs were also through increased upregulation of  amphiregulin, mice cotransferred with TregIL-33 
were injected with anti-amphiregulin antibody or isotype. We found that amphiregulin blockade in 
HCT recipients receiving TregIL-33 abolished the protective effect of  TregIL-33 compared with the isotype 
control (Figure 5C). These data indicated that TregIL-33 prevents GVHD through a dual mechanism: 
immunosuppression of  Teffs and upregulation of  amphiregulin in TregIL33.
Discussion
Since we have shown before that ST2+ Tregs prevent the development of  aGVHD in an experimental 
model (20), we aimed to investigate the mechanism by which this occurs. Our data first showed that 
ST2+ Tregs were expanded from donor tTregs following allo-HCT. They were predominantly localized 
in aGVHD target organs (gut and liver), but not in the secondary lymphoid organs, as reported for 
naive mice (22). We also found that absence of  ST2 on donor tTregs decreased their activation (CD69, 
KLRG1) and function (LAG3, IL-10) in the inflamed gut. We then performed transcriptome analysis of  
intestinal ST2–/– versus WT Tregs from the disparate Mhc and miH GVHD models and showed down-
regulation of  transcripts necessary for the function of  Tregs (Foxp3, Ctla4, Il27, Icos, Il1rl1, Il2ra, Ahr). 
As the loss of  Foxp3 expression has been shown to be associated with reversion to a more inflammatory 
phenotype in both transplant and nontransplant models (40–44), we looked at the gene transcription 
upregulated in intestinal ST2–/– Tregs as compared with intestinal WT Tregs from both HCT models. 
Most of  these genes were indeed involved in the inflammatory profile (Supplemental Table 2). Among 
these, Rorc was the only upregulated gene in intestinal ST2–/– Tregs in both HCT models. Tregs can be 
activated upon induction of  peripheral antigen encounter at barrier surfaces (45), which may explain 
why Rorc was more upregulated in Mhc versus miH GVHD recipients, as target antigen load and strength 
of  the TCR response to Mhc that drives proliferation are typically higher (46, 47).
Figure 3. Rorc–/– ST2+ Tregs decrease GVHD severity and mortality, increase intestinal ST2+ KLRG1+ Tregs after HCT, and decrease intestinal type 1 T 
cells. (A) Clinical scores and the survival curve of lethally irradiated C3H.SW mice that received B6 WT TCD BM and WT CD25-depleted total T cells with 
10% ST2+ Tregs isolated from WT or Rorc–/– mice. n = 7, from 2 independent experiments, data are shown as mean ± SEM; unpaired t test, *P < 0.05 for 
clinical scores; a log-rank test was used for survival analysis, **P < 0.01. (B) Representative plots of ST2 expression on Tregs isolated from the gut of C3H.
SW mice in A receiving WT or Rorc–/– ST2+ Tregs analyzed on day 14 after allo-HCT. n = 4, data are shown as mean ± SEM; unpaired t test, *P < 0.05. (C) 
Representative plots of ST2, KLRG1, and Helios expression on Foxp3+ Tregs from the gut of C3H.SW mice in A receiving WT or Rorc–/– ST2+ Tregs on day 14 
after HCT. n = 4, data are shown as mean ± SEM; unpaired t test, *P < 0.05. (D) Total infiltrated cells in the gastrointestinal (GI) tract of mice in A receiving 
WT or Rorc–/– ST2+ Tregs analyzed on day 14 after HCT. n = 4, data are shown as mean ± SEM; unpaired t test, *P < 0.05. (E) Representative plots of IFN-γ 
production by CD4+ and CD8+ Teffs from the gut of C3H.SW mice in A receiving WT or Rorc–/– ST2+ Tregs analyzed on day 14 after allo-HCT. n = 4, data are 
shown as mean ± SEM; unpaired t test, **P < 0.01, ***P < 0.001.
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Inflammatory signals, particularly cytokines, augment the differentiation of  activated T cells from rest-
ing T cells that circulate through the blood and lymphatics to reside in tissues rather than secondary lym-
phoid organs (18). Disease suppression by Tregs depends on endogenous antigen stimulation at the location 
in which Tregs reside that leads to the accumulation of  antigen-specific Tregs that can continuously negate 
pathogenic T cell response (48). Therefore, we next explored the role of  the IL-17 transcription factor Rorc 
in intestinal Tregs analyzed under steady state and inflamed gut conditions. In steady state, we showed that 
Tregs from Rorc–/– mice were more frequent and expressed higher levels of  ST2 compared with those from 
WT mice. Knocking down Rorc on T cells showed a reduction in GVHD severity (49), in accordance with 
our observation; here we showed that Tregs from Rorc–/– mice were more frequent and expressed higher lev-
els of  membrane-bound ST2, TIGIT, and Helios than those from WT mice during intestinal inflammation. 
Figure 4. Ex vivo polyclonal Tregs cultured with supplemental IL-33 (TregIL-33) express more ST2 and activation markers, and amphiregulin as com-
pared with those cultured without IL-33 or inhibited with IL-23/IL-17. (A) Representative plots of ST2 expression on B6 Tregs after different stimulation 
conditions (IL-2 [2 ng/ml]; IL-2 [2 ng/ml] + IL-33 [20 ng/ml]; IL-2 [2 ng/ml] + IL-33 [20 ng/ml] + IL-17 [40 ng/ml] + IL-23 [40 ng/ml]) for 3 days. Graphs show 
the frequency of ST2 expression on B6 Tregs. n = 10, data are shown as mean ± SEM; ANOVA with Bonferroni’s correction for multiple comparisons, ***P 
< 0.001. (B) Representative plots of KLRG1, LAG3, and Helios expression on B6 Tregs after different stimulation conditions (IL-2 [2 ng/ml]; IL-2 [2 ng/ml] 
+ IL-33 [20 ng/ml]; IL-2 [2 ng/ml] + IL-33 [20 ng/ml] + IL-23 [40 ng/ml]+ IL-17 [40 ng/ml] ) for 3 days. Graphs show the frequency of expression of KLRG1, 
LAG3, and Helios on B6 Tregs. n = 3, from 2 independent experiments, data are shown as mean ± SEM; ANOVA with Bonferroni correction for multiple 
comparisons, *P < 0.05, **P < 0.01, ***P < 0.001. (C) Representative plots of amphiregulin (AREG) expression on B6 Tregs after different stimulation con-
ditions (IL-2 [2 ng/ml]; IL-2 [2 ng/ml] + IL-33 [20 ng/ml]; IL-2 [2 ng/ml] + IL-33 [20 ng/ml] + IL-23 [40 ng/ml] + IL-17 [40 ng/ml]) for 3 days. For AREG analy-
sis, cells were stimulated for 3 hours with PMA and ionomycin in the presence of monensin. Graphs show the frequency and mRNA expression of AREG on 
B6 Tregs. n = 4, data are shown as mean ± SEM; ANOVA with Bonferroni’s correction for multiple comparisons, *P < 0.05, **P < 0.01, ***P < 0.001.
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This led to a shift in the balance of  Tcons, with decreased type 1 cells that secreted less sST2 and expressed 
more ST2 on their surface compared with WT T cells. In the present study, several mechanisms are possible: 
(i) cell-intrinsic, similar to a study showing the E3 ubiquitin ligase Itch is a negative regulator of  IL-17A 
production in colonic inflammation through targeting of  the transcription factor RORγt for proteasomal 
degradation (50); and (ii) indirect, favored by the intestinal cytokine and antigen milieu (18, 48, 51). 
Transplantation with Rorc–/– T cells has previously been shown to greatly diminish aGVHD severity (49, 
52–56), but transplantation with Rorc–/– Tregs, or ST2+ Tregs has not to our knowledge been done before. 
Since Tregs, particularly ST2+ Tregs, were enriched in Rorc–/– mice, it was important to verify whether ST2+ 
Tregs in Rorc–/– mice were qualitatively different from those in WT mice. It has been shown that in trans-
plant recipient mice, donor WT naive OT-II+ CD4+ T cells developed into RORγt+ Tregs when the mice 
were fed ovalbumin, whereas when mice received cells deficient in RORγt, a majority developed into Gata3+ 
Tregs, showing that a loss in RORγt affected Tregs through a cell-intrinsic pathway (57). In the current study, 
we show that ST2+ Tregs from Rorc–/– mice were able to decrease GVHD score and mortality as compared 
with ST2+ Tregs from WT mice, which indicated that ST2 was intrinsically associated with Rorc on Tregs.
We have recently shown in murine and human models that IL-9–producing T cells stimulated by the 
ST2/IL-33 pathway (T9IL-33) expressed amphiregulin and provided protection against epithelial damage 
Figure 5. Donor TregIL-33 improve GVHD compared with Tregs cultured without IL-33 or with IL-33 + IL-23/17, and AREG blockade abolishes the protective 
effect of TregIL-33. (A) Clinical score of aGVHD and survival curve for BALB/c mice receiving allogenic B6 CD25-replete T cells or CD25-depleted total T cells with 
ex vivo cultured Tregs (IL-2; IL-2 + IL-33; IL-2 + IL-33 + IL-23 + IL-17), ratio of 20:1. n = 10 per group, data are shown as mean ± SEM; ANOVA with Bonferroni’s 
correction for multiple comparisons, **P < 0.01, ***P < 0.001 for clinical score; a log-rank test was used for survival analysis, *P < 0.05, **P < 0.01, ***P < 
0.001. (B) Graphs represent total infiltrated cells in gut, and frequency of Foxp3, T-bet, RORγt, Ki-67, ST2, IFN-γ, IL-17 in infiltrated T cells isolated from the 
gut of BALB/c recipient mice on day 10 after allo-HCT. n = 4, data are shown as mean ± SEM; ANOVA with Bonferroni’s correction for multiple comparisons, 
*P < 0.05, **P < 0.01, ***P < 0.001. (C) Clinical score of aGVHD and survival curve for C3H.SW mice receiving allogenic B6 CD25-depleted total T cells with ex 
vivo cultured TregIL-33, ratio of 10:1. Mice were treated with five 100-μg doses of anti-amphiregulin or isotype control every other day from day –1 to day 7. n = 5 
per group, data are shown as mean ± SEM; unpaired t test, ***P < 0.001 for clinical score; a log-rank test was used for survival analysis, **P < 0.01. 
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from aGVHD (27). We proposed use of  T9IL-33 in the context of  malignant setting when GVL activity is 
needed. In the current study, we propose the use of  TregIL-33 as a cellular therapy to prevent GVHD in the 
context of  a nonmalignant setting, as Tregs need not have anticancer activity. Indeed, adoptive transfer 
of  ex vivo cultured donor Tregs has been shown by several groups in experimental (5–7) and clinical 
aGVHD (8–10). Several methods of  activation of  Tregs for translational purposes have been approved 
(58–61), and we propose here a new approach with a potential new mechanism of  Treg function. Studies 
have shown that IL-33 activation of  ST2+Tregs increases their suppressive function (19, 20). Peri-admin-
istration of  IL-33 expands recipient Tregs that protect mice against aGVHD (28). The administration 
of  recombinant IL-33 substantially expanded tissue ST2+ Tregs in all organs assessed: the number of  
tissue-resident ST2+ Tregs increased by 10-fold in fat, 5-fold in skin, 13-fold in liver, and 60-fold in lung 
tissue (22). These findings suggested that ST2+ Tregs were a distinct state in tissues and underwent pop-
ulation expansion via IL-33. We found that TregIL-33 were able to suppress CD4
+ Teffs only slightly more 
than control Tregs in vitro at lower Treg/Teff  ratios. These data were partly in contrast to the finding that 
showed suppressive function of  IL-33–cultured Tregs was not impaired at higher Treg/Teff  ratios (19). 
This could be due to different experimental conditions as well as different Treg/Teff  ratios. Indeed, in 
the latter study, Tregs and Teffs were cocultured in the presence of  IL-33 without prior in vitro activation 
of  Tregs with IL-33. In addition, the Treg/Teff  ratio was higher (1:1 and 1:3). In our conditions, we first 
cultured Tregs with IL-2 + IL-33 for 3 days to induce ST2 expression, then cocultured them with Teffs 
under different Treg/Teff  ratios (up to 1:24). As expected and similar to the above-mentioned study (19), 
ST2–/– Tregs did not show additional suppression ability, as Tregs did not respond to IL-33, indicating 
the suppression ability of  TregIL-33 was directly due to the expression of  ST2. In line with the previous 
study, we found adoptive transfer of  TregIL-33 ameliorated aGVHD via inhibiting the Teff  response in 
vivo. To explain the more modest suppressor function in the in vitro compared with the in vivo setting, 
we hypothesized that the substantial increase in GVHD inhibition in vivo by TregIL-33 may be due to 
increased expression in TregIL-33 of  amphiregulin that may contribute to GVHD inhibition as a result 
of  its tissue-reparative properties (shown in Figure 5C). Alternatively, the fact that LAG3, Helios, and 
KLRG1 levels were higher in 3-day in vitro cultures of  Tregs containing IL-33 may have contributed to 
improved GVHD protective effects by TregIL33. Indeed, one of  the important characteristics that was 
found for tissue-resident ST2+ Tregs in skin and fat was the production of  amphiregulin (22), which 
facilitated repair from muscle damage (37) and viral infection (38). Studies have suggested that IL-33 
also promotes amphiregulin expression on ILC2s, leading to intestinal tissue protection dependent on 
amphiregulin-EGFR interactions (62). Blocking amphiregulin after adoptive transfer of  T9IL-33 has been 
shown to reduce allogeneic mouse and human colonic epithelial survival in vitro and increase aGVHD 
severity in vivo (27). In the current study we showed that TregIL-33 also expressed higher amphiregulin in 
vitro. Importantly, blocking amphiregulin by neutralizing antibody in vivo abolished the protective effect 
of  TregIL-33 in the miH HCT model. Therefore, adoptive transfer of  ex vivo cultured donor TregIL-33 better 
protected from aGVHD intestinal damage compared with Tregs cultured without IL-33, possibly via syn-
ergistic immunosuppressive and amphiregulin-EGFR tissue protection mechanisms. Our data confirmed 
that adoptive transfer of  TregIL-33 is a viable therapeutic option.
Finally, we investigated whether inflammatory IL-23 and IL-17 can interfere with ST2 signaling in 
Tregs, and showed that IL-23 and IL-17 inhibit the effect of  IL-33 on Tregs both ex vivo and in vivo as shown 
with IL-23 on IL-33–induced pTregs in a colitis model (19). We did not find differences in Rorc expression 
on Tregs cultured under the 3 aforementioned conditions. It has been shown previously that IL-23 does not 
induce Rorc or Th17 cytokines in CD4+T cells isolated from a collagen-induced arthritis murine model (63). 
In addition, Schiering et al. showed that IL-23 limited T cell responsiveness to IL-33 by inhibiting expression 
of  GATA3 and ST2 in colonic Tregs in vitro and in vivo (19). We analyzed the whole transcriptome data 
published by Schiering et al. and compared Rorc gene expression in colonic effector CD4+ T cells between 
WT and IL-23r–/– mice; however, we did not find any difference (data not shown). We hypothesized that the 
short-term culture of  Tregs with IL-33 + IL-23 could not induce Rorc expression. Therefore, for allo-HCT, 
adding IL-33 to Treg expansion cultures might improve their protective effects in aGVHD. The effect of  
IL-33 on Tregs could be inhibited by adding IL-23 and IL-17 as in a colitis model (19), suggesting that early 
administration of  TregIL-33, before development of  an overwhelming Th17/Tc17 response, should be favored.
We conclude that within GVHD target organs, ST2+ Tregs are predominantly intestine localized, 
and inversely correlated with RORγt in steady-state and inflammatory conditions. Triggering the ST2/
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IL-33 pathway in Tregs prevents severe aGVHD, possibly through a dual mechanism: upregulation of  
amphiregulin and immunosuppression on Teffs. Thus, TregIL-33 represents a potential cellular therapy 
avenue for preventing aGVHD.
Methods
Mice. B6 (B6, H-2b, CD45.2+), B6 Foxp3RFP, B6 Rorc–/–, BALB/c (H-2d), and C3H.SW (H-2b, CD45.2+) 
mice were purchased from the Jackson Laboratory. B6 Foxp3GFP mice were provided by Matthew J. Turner 
(Indiana University); B6 ST2–/– (CD45.2+) mice were provided by Andrew McKenzie (University of  Cam-
bridge, Cambridge, United Kingdom) and were bred to B6 Foxp3GFP, and the homozygous ST2–/– Foxp3GFP 
genotype was confirmed by PCR.
Induction and assessment of  aGVHD. Mice underwent allo-BM transplantation as previously described 
(20, 64). Briefly, BALB/c and C3H.SW recipients received 900 and 1100 cGy total body irradiation (x-ray 
or 137Cs source, respectively) on day –1. Recipient mice were injected intravenously with TCD BM cells (5 
× 106) plus splenic T cells, 2 × 106 for C3H.SW or 1 × 106 for BALB/c allogeneic donors, on day 0. T cells 
from donor mice were enriched using the murine Pan T Cell Isolation Kit (Miltenyi Biotec), and TCD BM 
was prepared with CD90.2 Microbeads (Miltenyi Biotec). Mice were housed in sterilized Micro-Isolator 
cages and maintained on acidified water (pH <3) for 3 weeks. Survival was monitored daily, and clinical 
GVHD scores were assessed weekly as described previously (65). Mice were euthanized when clinical 
scores reached 6.5, in accordance with animal protocols approved by the Institutional Review Board.
Isolation of  intestinal cells. Single-cell suspensions were prepared from intestines as described previously 
(20). Briefly, intestines were flushed with PBS to remove fecal matter and mucus. Fragments (<0.5 cm) of  
intestines were digested in 10 ml DMEM containing collagenase type B (2 mg/ml; Roche), deoxyribonu-
clease I (10 μg/ml; Roche), and 4% bovine serum albumin (Sigma-Aldrich) at 37°C with shaking for 90 
minutes. The digested mixture was then diluted with 30 ml plain DMEM, filtered through a 70-μm strainer 
and centrifuged at 850 g for 10 minutes. The cell pellets were suspended in 5 ml of  80% Percoll (GE Health-
care), overlaid with 8 ml of  40% Percoll and spun at 1000 g for 20 minutes at 4°C without braking. Enriched 
lymphocytes were collected from the interface. At the University of  Minnesota, after intestines were flushed 
with PBS to remove mucus and fecal matter, Peyer patches were removed. Digestion of  tissue occurred over 
a 2-step process. Single-cell suspensions from 2 incubations of  the tissue fragments (1–1.5 cm) in 10 ml PBS 
containing 5 mM EDTA, 10 mM HEPES, and 2% FCS at 37°C for 10 minutes each were collected through a 
70-μm strainer. Remaining tissue was cut into smaller fragments (<0.5 cm) and digested in 10 ml RPMI con-
taining 5%FCS, 50 U/ml Dispase (Sigma-Aldrich), 0.5 mg/ml of  each Collagenase D (Roche) and DNase 
I (Sigma-Aldrich) for 60 minutes at 37°C, collecting single-cell suspensions through a 70-μm strainer and 
adding fresh digestion solution to the remaining tissue at 20-minute intervals. The digested tissue was filtered 
through a 70-μm strainer and centrifuged at 2000 g for 10 minutes. The cell pellets were suspended in 5 ml of  
80% Percoll (GE Healthcare), overlaid with 8 ml of  40% Percoll, and spun at 1400 g for 20 minutes at 20°C 
without braking. The enriched lymphocyte layer was collected from the interface.
Flow cytometry. All antibodies and reagents for flow cytometry were purchased from eBioscience, unless 
stated otherwise (see Supplemental Table 3). The cells were preincubated with purified anti–mouse CD16/
CD32 mAb for 10–20 minutes at 4°C to prevent nonspecific binding of  the antibodies. The cells were 
subsequently incubated for 30 minutes at 4°C with antibodies for surface staining. Fixable viability dye 
(FVD) was used to distinguish live cells from dead cells. The Foxp3/Transcription Factor Staining Buffer 
Set and the Fixation and Permeabilization Kit (Invitrogen) were used for intracellular transcription factor 
and cytokine staining. For cytokine staining, cells were restimulated with PMA (50 ng/ml), ionomycin (1 
μg/ml; Sigma-Aldrich), and brefeldin A for 4–6 hours before any staining. For the analysis of  amphiregulin 
production, ex vivo cultured Tregs were stimulated with PMA (50 ng/ml) and ionomycin (1 nM) for 3 
hours in the presence of  GolgiStop (monensin).
Cell sorting. Intestinal Tregs and CD4+ Tcons from C3H.SW recipient mice receiving allo-HCT were 
sorted based on Foxp3GFP expression. Foxp3GFP-expressing cells were collected from aGVHD mice on day 10 
or day 14 after transplantation of  allogeneic and further characterized by quantitative reverse transcription 
PCR (qPCR) and NanoString analysis. Cell sorting was performed using a BD FACSAria (BD Bioscience).
qPCR. Total RNA was isolated from sorted cells using the RNeasy Plus Mini Kit (QIAGEN). cDNA 
was prepared with a SuperScript VILO cDNA Synthesis Kit (Invitrogen). qPCR was performed using 
SYBR Green PCR mix on an ABI Prism 7500HT (Applied Biosystems). Thermocycler conditions included 
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2-minute incubation at 50°C, then 95°C for 10 minutes; this was followed by a 2-step PCR program of  95°C 
for 5 seconds and 60°C for 60 seconds for 40 cycles. β-Actin was used as an internal control. The primer 
sequences were as follows: actin forward 5′-CTCTGGCTCCTAGCACCATGAAGA-3′, reverse 5′-GTA-
AAACGCAGCTCAGTAACAGTCCG-3′; ST2 forward 5′-AAGGCACACCATAAGGCTGA-3′, reverse 
5′-TCGTAGAGCTTGCCATCGTT-3′; sST2 forward 5′-TCGAAATGAAAGTTCCAGCA-3′, reverse 
5′-TGTGTGAGGGACACTCCTTAC-3′; amphiregulin forward 5′-GGACAATGCAGGGTAAAAGTT-
GA-3′, reverse 5′-TGAAAGAAGGACCAATGTCATTTC-3′.
NanoString. Sorted Foxp3GFP+ Tregs from aGVHD mice were directly lysed in RLT buffer (QIAGEN) on 
ice. The cell concentration for lysis was 0.2 × 104 to 1 × 104 cells/μl in a total volume of  5 μl with RLT buffer. 
Lysis samples were immediately frozen in liquid nitrogen and then stored at −80°C or in dry ice. NanoString 
analysis was performed with the nCounter Analysis System at NanoString Technologies. The nCounter 
Mouse Immunology Kit, which includes 561 immunology-related mouse genes, was used in the study.
ELISA. Concentrations of  IFN-γ in plasma were measured with DuoSet ELISA Kits; sST2 was mea-
sured with Quantikine ELISA Kits (R&D Systems).
Treg isolation and stimulation. Mouse Tregs were isolated magnetically from fresh splenocytes of  Foxp3GFP 
B6 mice. Cells were plated at a concentration of  1 × 106 cells/ml and activated with 1 μg/ml plate-bound 
anti-CD3 (2C11) and 5–10 μg/ml soluble anti-CD28 (clone 37.51). Tregs were under different stimulation 
conditions: IL-2 (2 ng/ml); IL-2 (2 ng/ml) and IL-33 (20 ng/ml); IL-2 (2 ng/ml), IL-33 (20 ng/ml), IL-23 
(40 ng/ml), and IL-17 (40 ng/ml) for 3 days.
Immunosuppression assays. The ex vivo suppressive capacity of  cultured Tregs was assessed with a CTV 
inhibition assay as previously published (66). Briefly, CD4+ and CD8+ Teffs and antigen-presenting cells 
(APCs) were purified from B6 mice splenocytes. Teffs were labeled with CTV (Invitrogen) and plated 
together with the cultured Tregs at different ratios together with APCs in the presence of  anti-CD3 (0.25 
μg/ml). After 4 days, proliferation of  Teffs was measured by flow cytometry.
Adoptive transfer of  ST2+ Tregs. For the adoptive transfer model in minor-mismatched mice (B6, 
H-2b→C3H.SW, H-2b), Rorc–/– or WT B6 CD4+ T cells were isolated from Foxp3GFP mice using murine 
CD4+CD25+ Regulatory T Cell Isolation Kit (Miltenyi Biotec). Tregs were isolated by using APC anti-
mouse CD25 (eBioscience) and an Anti-APC MultiSort Kit (Miltenyi Biotec). ST2+ Tregs were further 
separated by using PE anti-mouse ST2 (MD bioproduct) and anti-PE microbeads (Miltenyi Biotec). A ratio 
of  1 ST2+ Treg per 10 CD25-depleted total T cells (10% of  total T cells in the graft) was used. TCD BM 
cells from WT B6 mice were prepared with CD90.2 Microbeads (Miltenyi Biotec).
Adoptive transfer of  ex vivo cultured TregIL-33 and control Tregs. For adoptive transfer models in major-mis-
matched (B6, H-2b→BALB/c, H-2d) and minor-mismatched (B6, H-2b→C3H.SW, H-2b) mice, first donor 
B6 Tregs were isolated from Foxp3GFP mice using murine CD4+CD25+ Regulatory T Cell Isolation Kit 
(Miltenyi Biotec) and ex vivo cultured for 3 days under the different conditions described above (IL-2, 
IL-2 + IL-33, IL-2 + IL-33 + IL-17 + IL-23). The day of  the transplantation, total B6 donor T cells were 
purified using the murine Pan T Cell Isolation Kit (Miltenyi Biotec), then CD25-depleted using the murine 
CD4+CD25+ Regulatory T Cell Isolation Kit (Miltenyi Biotec). A more stringent ratio of  1 cultured Treg 
per 20 CD25-depleted total T cells (5% of  total T cells in the graft) was used for the 3 cultured Tregs condi-
tions. As a control, one HCT group was transplanted with CD25-replete donor T cells without supplemen-
tal Tregs, thus containing a physiological ratio of  Tregs. TCD BM cells from donors were prepared with 
CD90.2 Microbeads (Miltenyi Biotec).
In vivo treatment with anti-AREG. C3H.SW recipients received 1,100 cGy total body irradiation (137Cs 
source) on day −1. On day 0, mice were injected intravenously with B6 TCD BM cells (5 × 106), 2 × 106 
WT CD25-depelted total T cells, and 10% ex vivo cultured WT TregIL-33. Mice received 5 doses of  100 μg 
anti-AREG or isotype control every other day from day −1 to day 7.
Microarray analysis. Microarray data were downloaded in the Gene Expression Omnibus under acces-
sion number GSE58164 (19). Microarray was performed using GeneSpring GX12 software (Agilent). 
Data were normalized using 75% percentile shift normalization algorithm and baseline transformed to the 
median of  all samples. Statistical significance was determined using an unpaired t test followed by Benja-
mini-Hochberg FDR multiple testing correction. The P value cutoff  was set to 0.05.
Statistics. Phenotypic and functional data were compared using unpaired t test for 2-group comparison 
and ANOVA test for comparison of  3 or more group. Prior to analysis, the normality assumption was 
examined. All tests were 2 sided at the significance level P < 0.05. To account for the type I error inflation 
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due to multiple comparisons, we applied Bonferroni’s correction. A log-rank test was used for survival anal-
ysis. The analyses were performed using Prism software version 7.03 (GraphPad), and data are presented 
as mean ± SEM.
Study approval. Animal experiments and euthanasia protocols performed in this study were approved by 
the Indiana University School of  Medicine IACUC (protocol 18033).
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